Sarepta Therapeutics SRPT has been analyzed by 14 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 5 | 5 | 0 | 0 | 4 |
| Last 30D | 0 | 0 | 0 | 0 | 1 |
| 1M Ago | 1 | 0 | 0 | 0 | 1 |
| 2M Ago | 1 | 1 | 0 | 0 | 2 |
| 3M Ago | 3 | 4 | 0 | 0 | 0 |
The 12-month price targets, analyzed by analysts, offer insights with an average target of $151.64, a high estimate of $205.00, and a low estimate of $75.00. Observing a downward trend, the current average is 4.38% lower than the prior average price target of $158.58.
Breaking Down Analyst Ratings: A Detailed Examination
A clear picture of Sarepta Therapeutics's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Mitchell Kapoor | HC Wainwright & Co. | Maintains | Sell | $75.00 | $75.00 |
| Gil Blum | Needham | Maintains | Buy | $202.00 | $202.00 |
| Mitchell Kapoor | HC Wainwright & Co. | Maintains | Sell | $75.00 | $75.00 |
| Mitchell Kapoor | HC Wainwright & Co. | Lowers | Sell | $75.00 | $80.00 |
| Biren Amin | Piper Sandler | Lowers | Overweight | $182.00 | $200.00 |
| Gil Blum | Needham | Lowers | Buy | $202.00 | $205.00 |
| Mitchell Kapoor | HC Wainwright & Co. | Announces | Sell | $80.00 | - |
| Whitney Ijem | Guggenheim | Raises | Buy | $150.00 | $148.00 |
| Brian Skorney | Baird | Lowers | Outperform | $193.00 | $200.00 |
| Kristen Kluska | Cantor Fitzgerald | Raises | Overweight | $167.00 | $152.00 |
| Gavin Clark-Gartner | Evercore ISI Group | Lowers | Outperform | $170.00 | $179.00 |
| Gil Blum | Needham | Maintains | Buy | $205.00 | $205.00 |
| Brian Abrahams | RBC Capital | Maintains | Outperform | $182.00 | $182.00 |
| Andrew Tsai | Jefferies | Announces | Buy | $165.00 | - |
Key Insights:
- Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Sarepta Therapeutics. This insight gives a snapshot of analysts' perspectives on the current state of the company.
- Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Sarepta Therapeutics compared to the broader market.
- Price Targets: Gaining insights, analysts provide estimates for the future value of Sarepta Therapeutics's stock. This comparison reveals trends in analysts' expectations over time.
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Sarepta Therapeutics's market standing. Stay informed and make data-driven decisions with our Ratings Table.
Stay up to date on Sarepta Therapeutics analyst ratings.
All You Need to Know About Sarepta Therapeutics
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's strategy involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Most of company's product candidates are at an early stage of development.
Sarepta Therapeutics: A Financial Overview
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Sarepta Therapeutics's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 40.79%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 7.19%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Sarepta Therapeutics's ROE stands out, surpassing industry averages. With an impressive ROE of 2.93%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Sarepta Therapeutics's ROA excels beyond industry benchmarks, reaching 0.96%. This signifies efficient management of assets and strong financial health.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 1.14.
Understanding the Relevance of Analyst Ratings
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. Click here for urgent details.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
